Physician profile
Brian Kern
NPI 1568920072
$275.50
in general payments reported to CMS, 2019-2025
11 companies · $133 in 2025
The $133 reported for 2025 was more than what 81% of Nurse Anesthetist, Certified Registered providers received nationally (typical 2025 total: $45.72).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2023: $58.86 · 2024: $83.77 · 2025: $133.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $276.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $275.50 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Takeda Pharmaceuticals U.S.A., INC. | $76.87 | 2023-2025 | Entyvio |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $37.14 | 2024-2025 | Xifaxan |
| Janssen Biotech, INC. | $21.90 | 2025 | Tremfya |
| Intercept Pharmaceuticals, INC. | $19.84 | 2023 | Ocaliva |
| Fisher & Paykel Healthcare INC | $19.25 | 2025 | Fisher & Paykel Healthcare |
| Lilly USA, LLC | $19.18 | 2025 | Omvoh |
| Edwards Lifesciences Corporation | $18.36 | 2024 | |
| Masimo Corporation | $17.88 | 2025 | Sedline |
| Genentech USA, INC. | $17.04 | 2024 | Ocrevus |
| Ardelyx, INC. | $14.22 | 2025 | Ibsrela |
| Aucta Pharmaceuticals, INC. | $13.82 | 2024 | Motpoly Xr |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Brian Kern listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.